Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 53

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 53
---
41.44.512.2150. To facilitate timely delivery of these documents, any request should be made no later than September15, 2025 to receive them before the extraordinary meeting of shareholders of NLS (the “NLS Meeting”). For additional details about where you can find information about NLS, please see the section entitled “ Where You Can Find More Information” in this proxy statement/prospectus. The contents of the websites of the SEC, NLS, Kadimastem, or any other entity are not being incorporated into this proxy statement/prospectus. The information about how you can obtain certain documents that are incorporated by reference into this proxy statement/prospectus at these websites is being provided only for your convenience. ABOUT THIS PROXY STATEMENT / PROSPECTUS This proxy statement/prospectus, which forms part of a registration statement on Form F -4filed with the SEC by NLS (File No. 333 -284075), constitutes a notice of meeting and proxy statement with respect to the NLS Meeting and a prospectus of NLS under Section 5 of the Securities Act of 1933, as amended, which is referred to as the Securities Act, with respect to the NLS Common Shares to be issued to Kadimastem shareholders pursuant to the Agreement and Plan of Merger, dated November 4, 2024, by and between NLS, NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd., which was further amended on January30, 2025, February17, 2025, May5, 2025, June5, 2025, July1, 2025, July18, 2025 and August29, 2025, or the Merger Agreement, providing for the merger of Merger Sub with and into Kadimastem, with Kadimastem continuing as the surviving entity in the merger, as a result of which: (i) Kadimastem will become a wholly -ownedsubsidiary of NLS and (ii) each issued and outstanding ordinary share of Kadimastem, no par value, or Kadimastem Ordinary Share, immediately prior to the consummation of the merger will no longer be outstanding and will automatically be cancelled, in exchange for the right of the holder thereof to receive a substantially equivalent security of NLS, or the Merger. NLS is providing these proxy materials in connection with the solicitation by the NLS Board of proxies to